Cost-effectiveness Analysis in R Using a Multi-state Modeling Survival Analysis Framework: A Tutorial

Medical Decision Making

Volumn 37, Issue 4, 2017, Pages 340-352

  Williams, Claire ^a   Lewsey, James D ^a   Briggs, Andrew H ^a   Mackay, Daniel F ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

cost effectiveness analysis; Markov models; probabilistic sensitivity analysis; survival analysis

Indexed keywords

CALCULATION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; FEMALE; HUMAN; MALE; PREDICTION; STATISTICAL MODEL; SURVIVAL ANALYSIS; SURVIVAL RATE; THINKING; CHRONIC LYMPHATIC LEUKEMIA; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; MARKOV CHAIN; MORTALITY; PROBABILITY; PROCEDURES;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MARKOV CHAINS; MODELS, STATISTICAL; PROBABILITY; SURVIVAL ANALYSIS;

EID: 85019128171     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X16651869     Document Type: Article

References (25)

1. Sonnenberg FA, Beck JR,. Markov models in medical decision making: a practical guide. Med Decis Making. 1993; 13 (4): 322-38.
2. Briggs A, Sculpher M., An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998; 13 (4): 397-409.
3. Sun X, Faunce T., Decision-analytical modelling in health-care economic evaluations. Eur J Health Econ. 2008; 9: 313-23.
4. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL,. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. Oxford, UK: Oxford University Press; 2005.
5. TreeAge Pro 2015, R1.0. Williamstown, MA: TreeAge Software; 2015. Available from: https://www.treeage.com
6. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2015. Available from: http://www.R-project.org/
7. Frederix GWJ,. Development of a framework for cohort simulation in cost-effectiveness analyses using a multistep ordinary differential equation solver algorithm in R. Med Decis Making. 2013; 33 (6): 780-92.
8. Hawkins N, Sculpher M, Epstein D., Cost-effectiveness of treatments for chronic disease: using R to incorporate time dependency of treatment response. Med Decis Making. 2005; 25: 511-9.
9. de Wreede LC, Fiocco M, Putter H., mstate: an R package for the analysis of competing risks and multi-state models. J Stat Software. 2011; 38 (7): 1-30.
10. Putter H, Fiocco M, Geskus RB., Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007; 26: 2389-430.
11. Latimer N,. NICE DSU Technical Support Document 14: undertaking survival analysis for economic evaluations alongside clinical trials-extrapolation with patient-level data. 2011. Available from: http://www.nicedsu.org.uk
12. de Wreede LC, Fiocco M, Putter H., The mstate package for estimation and prediction in non- and semi-parametric multi-state and competing risks models. Comput Methods Programs Biomed. 2010; 99: 261-74.
13. Akaike H., A new look at the statistical model identification. IEEE Trans Autom Control. 1974; 19 (6): 716-23.
14. Saltelli A, Chan K, Scott EM, eds. Sensitivity Analysis. Chichester, UK: John Wiley; 2000.
15. Briggs A, Claxton K, Schulpher M., Decision Modelling for Health Economic Evaluation. Oxford, UK: Oxford University Press; 2011.
16. Fenwick E, Marshall DA, Levy AR, Nichol G., Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation. BMC Health Serv Res. 2006; 6: 52.
17. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010; 376: 1164-74.
18. National Institute for Health and Clinical Excellence. Rituximab for the first line treatment of chronic lymphocytic leukaemia. Available from: http://guidance.nice.org.uk/TA174
19. Roche Products Limited. Rituximab for the 1st line treatment of chronic lymphocytic leukaemia. London, UK: National Institute for Health and Clinical Excellence; 2008. Available from: http://www.nice.org.uk/guidance/ta174/resources/roche-submission2
20. Mitchell M., Engauge Digitizer Version 4.1. Available from: http://digitizer.sourceforge.net
21. Hancock S, Wake B, Hyde C,. Fludarabine as first line therapy for chronic lymphocytic leukaemia. A West Midland Health Technology Assessment Collaboration; 2002. Available from: http://www.birmingham.ac.uk/Documents/college-mds/haps/projects/WMHTAC/REPreports/2002/Fludarabine.pdf
22. Structured Data LLC. The beta-PERT distribution. https://www.riskamp.com/beta-pert
23. Guyot P, Ades AE, Ouwens MJNM, Welton NJ., Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012; 12: 9.
24. Grieve R, Hawkins N, Pennington M., Extrapolation of survival data in cost-effectiveness analyses: improving the current state of play. Med Decis Making. 2013; 33 (6): 740-42.
25. Connock M, Hyde C, Moore D., Cautions regarding the fitting and interpretation of survival curves: examples from NICE single technology appraisals of drugs for cancer. Pharmacoeconomics. 2011; 29 (10): 827-37.